1. Home
  2. |Insights
  3. |Court Upholds AAA Injunction Based on Implied-in-Fact Contract

Court Upholds AAA Injunction Based on Implied-in-Fact Contract

Client Alert | 1 min read | 08.24.18

On July 30, the U.S. District Court for the Northern District of Texas issued a decision in Air Center Helicopters Inc. v. Starlite Investments Ireland Ltd et al. (Case No. 18-599), upholding a temporary injunction issued by the American Arbitration Association that granted Defendant Starlite Aviation Group (a C&M client) the right to continue performing helicopter services in support of U.S. military operations in Afghanistan. In seeking to vacate the AAA’s Injunction Order, Plaintiff argued that the arbitrator exceeded his powers by granting Defendant relief under an implied-in-fact contract theory, and contemporaneously sought a preliminary injunction preventing Defendant from enforcing the AAA Injunction Order (which the parties briefed on an expedited basis). The Court rejected Plaintiff’s arguments and denied both motions, holding that (i) “[Plaintiff] cannot show a likelihood of success on the merits regarding its petition,” such that “[Plaintiff]’s motion for preliminary injunction must necessarily be denied;” (ii) Plaintiff had “not met its high burden to show that the arbitrator imperfectly executed or exceeded his powers” in the AAA Injunction Order, and thus Plaintiff was not entitled to vacatur. The Court noted that its rulings were subject to a later determination as to whether the Court had jurisdiction to review the AAA Injunction Order.

On August 15, the Court ruled that “it did have jurisdiction to deny Plaintiff’s motions to vacate and for preliminary injunction,” and granted Defendant’s cross motion to confirm the AAA Injunction Order, reinforcing Defendant’s right to perform under its implied-in-fact contract.

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...